Selectivity profiling of the novel EP2 receptor antagonist, PF-04418948, in functional bioassay systems: Atypical affinity at the guinea pig EP2 receptor

British Journal of Pharmacology

Volumn 168, Issue 1, 2013, Pages 129-138

  Birrell, Mark A ^a   Maher, Sarah A ^a   Buckley, James ^a   Dale, Nicole ^a   Bonvini, Sara ^a   Raemdonck, Kristof ^a   Pullen, Nick ^b   Giembycz, Mark A ^c   Belvisi, Maria G ^a,d  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c UNIVERSITY OF CALGARY   (Canada)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

antagonist; EP2 receptor; functional response; PGE2

Indexed keywords

PF 04418948; PROSTAGLANDIN E RECEPTOR 2; PROSTAGLANDIN E RECEPTOR 2 ANTAGONISM; PROSTAGLANDIN E2; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEPOLARIZATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; GUINEA PIG; HUMAN; HUMAN TISSUE; MALE; MOUSE; MUSCLE CONTRACTION; MUSCLE RELAXATION; NONHUMAN; PRIORITY JOURNAL; RAT; TRACHEA; VAGUS NERVE;

ANIMALS; AZETIDINES; BIOLOGICAL ASSAY; GUINEA PIGS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MUSCLE CONTRACTION; MUSCLE, SMOOTH; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, PROSTAGLANDIN E, EP2 SUBTYPE; TRACHEA;

EID: 84872856839     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.02088.x     Document Type: Article

References (32)

1. Abramovitz M, Adam M, Boie Y, Carrière M, Denis D, Godbout C, et al,. (2000). The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogues. Biochim Biophys Acta 1483: 285-293.
2. Alexander SP, Mathie A, Peters JA, (2011). Guide to receptors and channels (GRAC), 3rd edition. Br J Pharmacol 153 (Suppl. 2): S1-S209.
3. Amano H, Hayashi I, Endo H, Kitasato H, Yamashina S, Maruyama T, et al,. (2003). Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. J Exp Med 197: 221-232.
4. Benyahia C, Gomez I, Kanyinda L, Boukais K, Danel C, Leséche G, et al,. (2012). PGE(2) receptor (EP(4)) agonists: potent dilators of human bronchi and future asthma therapy? Pulm Pharmacol Ther 25: 115-118.
5. Birrell MA, DeAlba J, Catley MC, Hardaker E, Wong S, Collins M, et al,. (2008). Liver X receptor agonists increase airway reactivity in a model of asthma via increasing airway smooth muscle growth. J Immunol 181: 4265-4271.
6. Birrell MA, Belvisi MG, Grace M, Sadofsky L, Faruqi S, Hele DJ, et al,. (2009). TRPA1 agonists evoke coughing in guinea pig and human volunteers. Am J Respir Crit Care Med 180: 1042-1047.
7. Buckley J, Birrell MA, Maher SA, Nials AT, Clarke DL, Belvisi MG, (2011). EP4 receptor as a new target for bronchodilator therapy. Thorax 66: 1029-1035.
8. Coleman RA, Kennedy I, (1985). Characterisation of the prostanoid receptors mediating contraction of guinea-pig isolated trachea. Prostaglandins 29: 363-375.
9. Coleman RA, Kennedey I, Humphrey PPA, Lumley P, (1984). Prostanoid receptors-the development of a working classification. Trends Pharmacol Sci 5: 303-306.
10. 2) antagonist. Br J Pharmacol 164: 1847-1856.
11. 2. Am J Physiol Lung Cell Mol Physiol 281: L469-L474.
12. Gaddum JH, (1957). Theories of drug antagonism. Pharmacol Rev 9: 211-218.
13. 1phenyl)-1- cyclopenten-1-yl]-2-pyridinecarboxylic acid, GW848687X, a potent and selective prostaglandin EP1 receptor antagonist for the treatment of inflammatory pain. Bioorg Med Chem Lett 17: 385-389.
14. Henry PJ, Goldie RG, (1990). Beta 1-adrenoceptors mediate smooth muscle relaxation in mouse isolated trachea. Br J Pharmacol 99: 131-135.
15. Jones RL, Giembycz MA, Woodward DF, (2009). Prostanoid receptor antagonists: development strategies and therapeutic applications. Br J Pharmacol 158: 104-145.
16. Kabashima K, Saji T, Murata T, et al,. (2002). The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J Clin Invest 109: 883-894.
17. Karim SM, Sandler M, Williams ED, (1967). Distribution of prostaglandins in human tissues. Br J Pharmacol Chemother 31: 340-344.
18. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 1577-1579.
19. Lyford SJ, McKechnie K, (1994). Characterisation of the prostaglandin E2 sensitive (EP) receptor in the isolated rat trachea. Br J Pharmacol 112: 133-136.
20. McGrath J, Drummond G, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
21. McKenniff M, Rodger IW, Norman P, Gardiner PJ, (1988). Characterisation of receptors mediating the contractile effects of prostanoids in guinea-pig and human airways. Eur J Pharmacol 153: 149-159.
22. Maher SA, Birrell MA, Belvisi MG, (2009). Prostaglandin E2 mediates cough via the EP3 receptor: implications for future disease therapy. Am J Respir Crit Care Med 180: 923-928.
23. Narumiya S, Sugimoto Y, Ushikubi F, (1999). Prostanoid receptors: 23 structures, properties, and functions. Physiol Rev 79: 1193-1226.
24. Ndukwu IM, White SR, Leff AR, Mitchell RW, (1997). EP1 receptor blockade attenuates both spontaneous tone and PGE2-elicited contraction in guinea pig trachealis. Am J Physiol 273: L626-L633.
25. Neubig RR, Spedding M, Kenakin T, Christopoulos A, International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification (2003). International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacol Rev 55: 597-606.
26. 2 receptor agonist. Cardiovasc Drug Rev 11: 165-179.
27. Schild HO, (1949). pAx and competitive drug antagonism. Br J Pharmacol Chemother 4: 277-280.
28. 2 in mice. J Appl Physiol 88: 2214-2218.
29. Suzawa T, Miyaura C, Inada M, Maruyama T, Sugimoto Y, Ushikubi F, et al,. (2000). The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs. Endocrinology 141: 1554-1559.
30. 2 on airway tone. Am J Physiol Lung Cell Mol Physiol 284: L599-L606.
31. Waud DR, Son SL, Waud BE, (1978). Kinetic and empirical analysis of dose-response curves illustrated with a cardiac example. Life Sci 22: 1275-1285.
32. Woodward DF, Jones RL, Narumiya S, (2011). International Union of Basic and Clinical Pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress. Pharmacol Rev 63: 471-538.